// App-Quantinova.ai

1326 : A bifunctional tumor activated immunomodulator (TRACIr) targeting PD-L1 And CD28 Is a potent enhancer of T cell-mediated anti-tumor activity

Researchers

Presenter

  • Thomas DiRaimondo

Principal Investigators

  • Lina Ma

  • Simon Shenhav

  • Vanessa Cicchini

  • Robert Navert

  • Hua Wu

  • Renee Jocic

  • Cuiling Yu

  • Diane Aceveda

  • Hannah Best

  • Clara Prentiss

  • Kai Muskat

  • JASON CHANG

  • Farhad Dastmalchi

  • Fabrece Roup

  • Carolina Caffaro

  • Hans Aerni

  • Wayne Godfrey

  • Charles Winter

  • Marc Nasoff

  • Neil Gibson

  • David Campbell

  • Shahram Salek-Ardakan

Medical Centers

  • Fate Therapeutics, San Diego, CA, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Non Small Cell Lung cancer

  • Small cell lung cancer

  • Breast cancer

  • Lung Cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 2AP

  • Programmed death-ligand 1

  • tumor-infiltrating lymphocytes

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • TGN1412

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved